The Division of Gastrointestinal (GI) and Liver Pathology is led by Dr. Wendy Frankel, and the other faculty members include Drs. William Marsh, Martha Yearsley, James Liu and Jeff Kneile. Dr. Martha Yearsley will take over as the Director of Liver Pathology in the upcoming year. Our GI and liver fellowship continues to attract high quality fellows. We have recently recruited our fellow, Dr. Xiaoping Zhou, to join our division.
Our clinical volume continues to increase as new GI oncologic surgeons and gastroenterologists have already joined our team. We use molecular tests on some colorectal tumors with Dr. John Zhao in our molecular division, including Kras and Braf mutational analysis. The results of Kras and possibly Braf analysis will help guide future therapeutic decisions. We are involved in the James Oncologic Tumor Board conferences and attend other GI, pancreas and liver clinical conferences.
Our division is actively involved in translational research in several areas; the most active include colorectal and pancreatic carcinoma. Collaborations with Cancer Genetics and Dr. Albert de la Chapelle are at the forefront of our research efforts. The Ohio State University continues to be a leading center in research on colorectal carcinoma and Lynch Syndrome and with the support of Oncologic Surgery, Oncology and Cancer Genetics, we routinely screen colorectal carcinoma patients at OSU to evaluate for microsatellite instability and Lynch Syndrome. Other centers across the nation have adopted this practice, and we are considered one of the leading centers for this initiative. Dr. Frankel has been invited to several other institutions and national venues to lecture on this subject. We continue to work closely with Cancer Genetics to constantly re-evaluate ways to care for our patients. There is currently great interest in using the results of these tests to help guide decisions on the use of various chemotherapeutic agents. Investigations into other syndromes with a possible genetic association such as hyperplastic (serrated) polyposis are ongoing.
Other important collaborators include Drs. Mark Bloomston, Carlo Croce, Kay Huebner, Tom Schmittgen, Kalpana Ghoshal, and Samson Jacobs. New antibodies have been evaluated in the research setting and several of these are now a clinically important part of our activity. Many of our projects were presented at meetings during this time including the United States and Canadian Academy of Pathology and the American Society of Clinical Pathology. Our service has been active with the CALGB grant and Dr. Frankel is the GI Pathology Cadre leader and vice-chair of Pathology with the support of Dr. James Liu, who is a member of the GI Pathology Cadre. We are also active in the Cooperative Human Tissue Network (CHTN) grant with Dr. Frankel and Dr. Marsh involved. The CHTN grant is a critical resource for procurement of tissue for research for many OSU and outside investigators.
In addition to research activities, we are very dedicated to our teaching mission and are involved in teaching medical students, surgical oncology and gastroenterology fellows, and pathology residents and fellows. We are active at the national and international level with invited lectures and short courses at USCAP and other visiting professorships.